Multiple courses of immunotherapy with different immune cell types for patients with hepatocellular carcinoma after microwave ablation

The aim of the present study was to investigate the therapeutic efficacy of immunotherapy after microwave ablation (MWA), which was used to improve liver function, reduce the recurrence rate and enhance survival period in patients with hepatocellular carcinoma (HCC). Between February 2009 and Decemb...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2015-10, Vol.10 (4), p.1460-1466
Main Authors: YU, MING-AN, LIANG, PING, YU, XIAO-LING, HAN, ZHI-YU, DONG, XUE-JUAN, WANG, YU, CHENG, CHAO, LI, XIN
Format: Article
Language:English
Subjects:
Blood
Care and treatment
Cytokines
Cytotoxicity
Dendritic cells
Hepatitis
hepatocellular carcinoma
Hepatoma
Immunotherapy
Liver cancer
Lymphatic system
Lymphocytes
microwave ablation
Mortality
NMR
Nuclear magnetic resonance
Patient outcomes
Patients
recurrence
Studies
T cell receptors
T-lymphocyte
Tumors
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of the present study was to investigate the therapeutic efficacy of immunotherapy after microwave ablation (MWA), which was used to improve liver function, reduce the recurrence rate and enhance survival period in patients with hepatocellular carcinoma (HCC). Between February 2009 and December 2010, 14 patients received immunotherapy after MWA (immunotherapy group) and 15 patients received MWA alone with no post-ablated adjuvant therapy (control group). Immune and liver parameters, recurrence rate and survival time were recorded. The absolute lymphocyte count in the immunotherapy group exceeded that in the control group after 3 courses of immunotherapy (P0.05); however, certain cytotoxic subsets (CD3+/CD8+, CD8+CD28+ and CD3+CD16+CD56+ T cells) were over-represented and negative regulatory or helper subsets (CD4+CD8+, CD4+, CD4+CD25+) were under-represented in the immunotherapy group between 1 and 12 months after immunotherapy (P
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2015.2681